Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial

2.50
Hdl Handle:
http://hdl.handle.net/2336/34733
Title:
Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial
Authors:
Thjodleifsson, B; Beker, J A; Dekkers, C; Bjaaland, T; Finnegan, V; Humphries, T J
Citation:
Dig. Dis. Sci. 2000, 45(5):845-53
Issue Date:
1-May-2000
Abstract:
Gastroesophageal reflux disease (GERD) is a chronic condition, with 50-80% of patients experiencing recurrence within one year of completing initial treatment. In patients with erosive GERD, proton-pump inhibitors (PPI) provide faster healing and symptom relief than do H2-receptor antagonists and have become the treatment of choice. Rabeprazole is a new PPI with demonstrated efficacy in both the acute and maintenance treatment of erosive GERD. The primary objective was to compare efficacy and tolerability of rabeprazole and omeprazole in preventing relapse of healed erosive GERD. Secondary objectives included comparison of efficacy in preventing GERD relapse symptoms and in maintaining quality of life. In this multicenter, double-blind, parallel-group study, 243 patients with healed erosive GERD were randomised to receive rabeprazole 10 mg once daily in the morning (QAM) (N = 82); rabeprazole 20 mg QAM (N = 78); or omeprazole 20 mg QAM (N = 83). Endoscopies were performed at weeks 13, 26, 39 (if clinically indicated), and 52, or when symptoms suggested recurrence. Corpus biopsies were performed at each endoscopy, and antral biopsies were performed at study entry and exit. Rabeprazole 10 mg and 20 mg QAM were equivalent to omeprazole 20 mg QAM for all efficacy parameters. At week 52, relapse rates in the intent-to-treat populations were 5%, 4%, and 5% for rabeprazole 10 mg and 20 mg and omeprazole 20 mg, respectively. All treatments were well tolerated. In conclusion, both rabeprazole 10 mg and 20 mg QAM are equivalent to omeprazole 20 mg QAM in preventing recurrence of erosive GERD.
Description:
To access publisher full text version of this article. Please click on the hyperlink in Additional Links field
Additional Links:
http://www.springerlink.com/content/t12m0782t47h6765

Full metadata record

DC FieldValue Language
dc.contributor.authorThjodleifsson, B-
dc.contributor.authorBeker, J A-
dc.contributor.authorDekkers, C-
dc.contributor.authorBjaaland, T-
dc.contributor.authorFinnegan, V-
dc.contributor.authorHumphries, T J-
dc.date.accessioned2008-08-07T11:31:50Z-
dc.date.available2008-08-07T11:31:50Z-
dc.date.issued2000-05-01-
dc.date.submitted2008-08-07-
dc.identifier.citationDig. Dis. Sci. 2000, 45(5):845-53en
dc.identifier.issn0163-2116-
dc.identifier.pmid10795744-
dc.identifier.doi10.1023/A:1005548318996-
dc.identifier.urihttp://hdl.handle.net/2336/34733-
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fielden
dc.description.abstractGastroesophageal reflux disease (GERD) is a chronic condition, with 50-80% of patients experiencing recurrence within one year of completing initial treatment. In patients with erosive GERD, proton-pump inhibitors (PPI) provide faster healing and symptom relief than do H2-receptor antagonists and have become the treatment of choice. Rabeprazole is a new PPI with demonstrated efficacy in both the acute and maintenance treatment of erosive GERD. The primary objective was to compare efficacy and tolerability of rabeprazole and omeprazole in preventing relapse of healed erosive GERD. Secondary objectives included comparison of efficacy in preventing GERD relapse symptoms and in maintaining quality of life. In this multicenter, double-blind, parallel-group study, 243 patients with healed erosive GERD were randomised to receive rabeprazole 10 mg once daily in the morning (QAM) (N = 82); rabeprazole 20 mg QAM (N = 78); or omeprazole 20 mg QAM (N = 83). Endoscopies were performed at weeks 13, 26, 39 (if clinically indicated), and 52, or when symptoms suggested recurrence. Corpus biopsies were performed at each endoscopy, and antral biopsies were performed at study entry and exit. Rabeprazole 10 mg and 20 mg QAM were equivalent to omeprazole 20 mg QAM for all efficacy parameters. At week 52, relapse rates in the intent-to-treat populations were 5%, 4%, and 5% for rabeprazole 10 mg and 20 mg and omeprazole 20 mg, respectively. All treatments were well tolerated. In conclusion, both rabeprazole 10 mg and 20 mg QAM are equivalent to omeprazole 20 mg QAM in preventing recurrence of erosive GERD.en
dc.language.isoenen
dc.publisherSpringer Science + Business Mediaen
dc.relation.urlhttp://www.springerlink.com/content/t12m0782t47h6765en
dc.subject.mesh2-Pyridinylmethylsulfinylbenzimidazolesen
dc.subject.meshAdulten
dc.subject.meshAgeden
dc.subject.meshAnti-Ulcer Agentsen
dc.subject.meshBenzimidazolesen
dc.subject.meshDose-Response Relationship, Drugen
dc.subject.meshDouble-Blind Methoden
dc.subject.meshDrug Administration Scheduleen
dc.subject.meshEsophagitis, Pepticen
dc.subject.meshEuropeen
dc.subject.meshFemaleen
dc.subject.meshHumansen
dc.subject.meshMaleen
dc.subject.meshMiddle Ageden
dc.subject.meshOmeprazoleen
dc.subject.meshRecurrenceen
dc.subject.meshStomach Ulceren
dc.subject.meshTreatment Outcomeen
dc.titleRabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trialen
dc.typeArticleen
dc.contributor.departmentNational Hospital of Iceland, Reykjavik.en
dc.identifier.journalDigestive diseases and sciencesen

Related articles on PubMed

All Items in Hirsla are protected by copyright, with all rights reserved, unless otherwise indicated.